PMID: 11604556Oct 18, 2001Paper

Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033

Anti-cancer Drugs
M A GiesegW A Denny

Abstract

Irreversible inhibitors of the epidermal growth factor receptor (EGFR) are showing promise in clinical trials. This report is the first to show that inhibition of the EGFR tyrosine kinase by an irreversible binder synergizes with cisplatin, at least in EGFR-overexpressing tissue culture cell lines in vitro. Unlike previous synergies demonstrated between ErbB2 blockade and DNA-damaging drugs, the synergy between the irreversible EGFR inhibitor and cisplatin does not appear to involve the repair of DNA-cisplatin adducts. Given the current clinical data, this combination may be of more than theoretical interest.

References

Jul 7, 1992·Biochemical Pharmacology·G L Evans, J D Gralla
Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·J S MymrykT K Archer
Aug 17, 1996·Mutation Research·B J Sanderson, A J Shield
Mar 5, 1997·Journal of the National Cancer Institute·J Mendelsohn, Z Fan
Jan 1, 1997·Progress in Nucleic Acid Research and Molecular Biology·D Mu, A Sancar
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·D W FryE M Dobrusin
May 1, 1999·Seminars in Oncology Nursing·H A Taylor
Jul 14, 1999·FEBS Letters·I Sánchez-Pérez, R Perona
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaJ Mendelsohn
Nov 23, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·C M Perry, L R Wiseman

❮ Previous
Next ❯

Citations

Dec 17, 2011·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Yan ZhangJian Chen
Aug 23, 2002·Pharmacology & Therapeutics·William A Denny
Apr 2, 2003·Expert Opinion on Therapeutic Targets·Peter Traxler
Jan 14, 2012·Expert Opinion on Therapeutic Targets·Parthasarathy SeshacharyuluSurinder K Batra
Aug 27, 2005·Expert Opinion on Biological Therapy·Apar Kishor Ganti, Anil Potti
Oct 15, 2008·Cancer Investigation·Susana M Campos
Jan 18, 2008·Journal of Pharmaceutical Sciences·Jose L Mauriz, Javier González-Gallego
Jan 25, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chun-Ming TsaiKuo-Ting Chang
Apr 10, 2013·Critical Reviews in Oncology/hematology·Constance ThibaultYazid Belkacémi
Nov 12, 2002·Clinical Breast Cancer·Fatima CardosoAngelo Di Leo
Feb 28, 2007·Critical Reviews in Oncology/hematology·Olivier DassonvilleGerard Milano
Dec 9, 2004·Biochimica Et Biophysica Acta·Jeff CummingsCaroline Dive
Jul 6, 2004·Clinical Biochemistry·Srinivasan Madhusudan, Trivadi S Ganesan
Feb 18, 2003·Otolaryngologic Clinics of North America·Jill Gilbert, Arlene A Forastiere
Feb 13, 2015·Frontiers in Oncology·Xiaochun WangJia-Lin Yang
Dec 6, 2003·The Oncologist·Maarten L Janmaat, Giuseppe Giaccone
Jul 22, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda L GarlandJoseph P Eder
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John NemunaitisRalph G Zinner
Jun 19, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CastilloG Milano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.